| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| AIDS Vaccines | 18 | 2021 | 152 | 6.410 |
Why?
|
| HIV Infections | 79 | 2023 | 5097 | 5.210 |
Why?
|
| HIV-1 | 25 | 2021 | 1260 | 2.630 |
Why?
|
| Infectious Disease Transmission, Vertical | 20 | 2023 | 472 | 2.530 |
Why?
|
| Female | 79 | 2023 | 9103 | 1.950 |
Why?
|
| Humans | 97 | 2024 | 14537 | 1.910 |
Why?
|
| Sexual Behavior | 13 | 2021 | 320 | 1.860 |
Why?
|
| South Africa | 62 | 2024 | 7596 | 1.850 |
Why?
|
| Pregnancy Complications, Infectious | 14 | 2022 | 529 | 1.680 |
Why?
|
| Male | 50 | 2021 | 6754 | 1.600 |
Why?
|
| Adult | 54 | 2021 | 5913 | 1.600 |
Why?
|
| Adolescent | 32 | 2021 | 2985 | 1.500 |
Why?
|
| Sex Workers | 5 | 2021 | 116 | 1.440 |
Why?
|
| Noncommunicable Diseases | 3 | 2020 | 77 | 1.390 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 4 | 2014 | 20 | 1.270 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 3 | 2014 | 6 | 1.260 |
Why?
|
| Young Adult | 28 | 2021 | 2498 | 1.250 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 3 | 2014 | 29 | 1.250 |
Why?
|
| Anti-HIV Agents | 12 | 2019 | 1324 | 1.160 |
Why?
|
| Cross-Sectional Studies | 19 | 2021 | 1422 | 1.120 |
Why?
|
| Genetic Vectors | 4 | 2021 | 55 | 1.080 |
Why?
|
| Mothers | 6 | 2014 | 195 | 1.080 |
Why?
|
| Vaccines, DNA | 2 | 2016 | 11 | 1.040 |
Why?
|
| Adolescent Behavior | 3 | 2015 | 60 | 0.950 |
Why?
|
| Pre-Exposure Prophylaxis | 4 | 2021 | 196 | 0.950 |
Why?
|
| Directive Counseling | 2 | 2015 | 15 | 0.930 |
Why?
|
| Risk-Taking | 5 | 2020 | 121 | 0.930 |
Why?
|
| Parent-Child Relations | 2 | 2014 | 16 | 0.900 |
Why?
|
| Reproductive Health | 2 | 2015 | 51 | 0.890 |
Why?
|
| Condoms | 5 | 2020 | 88 | 0.860 |
Why?
|
| HIV Antibodies | 6 | 2021 | 247 | 0.850 |
Why?
|
| Ambulatory Care Facilities | 4 | 2020 | 125 | 0.840 |
Why?
|
| Immunization, Secondary | 3 | 2021 | 72 | 0.830 |
Why?
|
| CD4 Lymphocyte Count | 14 | 2017 | 656 | 0.830 |
Why?
|
| Circumcision, Male | 3 | 2019 | 99 | 0.800 |
Why?
|
| Vaccines | 1 | 2023 | 86 | 0.760 |
Why?
|
| Vaginal Smears | 2 | 2021 | 34 | 0.760 |
Why?
|
| Anti-Retroviral Agents | 5 | 2017 | 551 | 0.750 |
Why?
|
| Papanicolaou Test | 1 | 2021 | 29 | 0.740 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2021 | 115 | 0.730 |
Why?
|
| Polysorbates | 1 | 2021 | 10 | 0.730 |
Why?
|
| Squalene | 1 | 2021 | 10 | 0.730 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2021 | 103 | 0.730 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 23 | 0.730 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 39 | 0.720 |
Why?
|
| Immunoglobulin G | 3 | 2020 | 231 | 0.700 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 74 | 0.700 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 43 | 0.670 |
Why?
|
| Vaccination | 6 | 2023 | 365 | 0.660 |
Why?
|
| Breast Feeding | 5 | 2014 | 120 | 0.640 |
Why?
|
| Viral Load | 12 | 2017 | 819 | 0.630 |
Why?
|
| Violence | 3 | 2018 | 68 | 0.630 |
Why?
|
| HIV | 3 | 2017 | 380 | 0.630 |
Why?
|
| Pregnancy | 19 | 2022 | 1862 | 0.630 |
Why?
|
| Antibodies, Neutralizing | 3 | 2023 | 303 | 0.620 |
Why?
|
| Adolescent Health Services | 2 | 2018 | 17 | 0.620 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2016 | 187 | 0.600 |
Why?
|
| Poverty | 2 | 2020 | 152 | 0.600 |
Why?
|
| Mental Health | 3 | 2020 | 91 | 0.600 |
Why?
|
| Intimate Partner Violence | 2 | 2017 | 55 | 0.590 |
Why?
|
| HIV Envelope Protein gp120 | 3 | 2016 | 104 | 0.570 |
Why?
|
| Prevalence | 10 | 2021 | 1192 | 0.570 |
Why?
|
| Sex Work | 1 | 2017 | 39 | 0.560 |
Why?
|
| Adenoviridae | 2 | 2014 | 39 | 0.550 |
Why?
|
| Safe Sex | 3 | 2018 | 68 | 0.550 |
Why?
|
| Drug Resistance, Viral | 2 | 2017 | 278 | 0.520 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2016 | 52 | 0.510 |
Why?
|
| Infant, Newborn | 15 | 2023 | 1479 | 0.500 |
Why?
|
| Immunization Schedule | 1 | 2016 | 81 | 0.500 |
Why?
|
| Middle Aged | 13 | 2020 | 3601 | 0.490 |
Why?
|
| Double-Blind Method | 7 | 2021 | 272 | 0.490 |
Why?
|
| CD4-CD8 Ratio | 1 | 2015 | 4 | 0.490 |
Why?
|
| Sex Education | 1 | 2015 | 17 | 0.480 |
Why?
|
| Risk Factors | 12 | 2021 | 1475 | 0.470 |
Why?
|
| Socioeconomic Factors | 6 | 2015 | 411 | 0.470 |
Why?
|
| Lactation | 1 | 2014 | 12 | 0.470 |
Why?
|
| Depression | 5 | 2021 | 121 | 0.460 |
Why?
|
| HIV Antigens | 6 | 2019 | 26 | 0.460 |
Why?
|
| Tenofovir | 3 | 2021 | 171 | 0.460 |
Why?
|
| Immunoglobulin A | 1 | 2014 | 39 | 0.460 |
Why?
|
| Prospective Studies | 10 | 2020 | 1160 | 0.450 |
Why?
|
| Protein Precursors | 1 | 2014 | 22 | 0.450 |
Why?
|
| Antibodies, Monoclonal | 3 | 2021 | 142 | 0.450 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2020 | 256 | 0.450 |
Why?
|
| Communication | 1 | 2014 | 57 | 0.430 |
Why?
|
| Decision Making | 2 | 2014 | 53 | 0.420 |
Why?
|
| Unsafe Sex | 1 | 2013 | 46 | 0.410 |
Why?
|
| Zidovudine | 3 | 2009 | 59 | 0.390 |
Why?
|
| Patient Participation | 1 | 2011 | 13 | 0.380 |
Why?
|
| Adenoviruses, Human | 1 | 2010 | 11 | 0.350 |
Why?
|
| Women's Health | 2 | 2009 | 41 | 0.340 |
Why?
|
| Tuberculosis | 7 | 2020 | 543 | 0.330 |
Why?
|
| Surveys and Questionnaires | 7 | 2020 | 563 | 0.320 |
Why?
|
| Fertility | 1 | 2009 | 22 | 0.320 |
Why?
|
| Incidence | 7 | 2021 | 685 | 0.320 |
Why?
|
| Cell Phone | 2 | 2020 | 34 | 0.310 |
Why?
|
| Nevirapine | 3 | 2009 | 146 | 0.310 |
Why?
|
| Intention | 1 | 2009 | 23 | 0.310 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 71 | 0.310 |
Why?
|
| Contraception Behavior | 1 | 2009 | 54 | 0.310 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 104 | 0.310 |
Why?
|
| Immunization, Passive | 2 | 2020 | 17 | 0.300 |
Why?
|
| Mass Screening | 2 | 2020 | 245 | 0.300 |
Why?
|
| Treatment Outcome | 6 | 2020 | 889 | 0.290 |
Why?
|
| Infant | 13 | 2020 | 2244 | 0.290 |
Why?
|
| Placebos | 3 | 2019 | 44 | 0.290 |
Why?
|
| Pandemics | 2 | 2020 | 296 | 0.290 |
Why?
|
| Pain Management | 1 | 2007 | 12 | 0.290 |
Why?
|
| Sex Characteristics | 1 | 2007 | 43 | 0.290 |
Why?
|
| Interferon-gamma | 3 | 2019 | 39 | 0.280 |
Why?
|
| Immunologic Factors | 1 | 2007 | 9 | 0.280 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 370 | 0.270 |
Why?
|
| Focus Groups | 5 | 2020 | 196 | 0.270 |
Why?
|
| Cohort Studies | 9 | 2021 | 967 | 0.270 |
Why?
|
| Substance-Related Disorders | 3 | 2015 | 51 | 0.260 |
Why?
|
| Sex Offenses | 2 | 2017 | 29 | 0.260 |
Why?
|
| Enzyme-Linked Immunospot Assay | 2 | 2016 | 10 | 0.250 |
Why?
|
| Reproductive Health Services | 2 | 2018 | 66 | 0.250 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2020 | 151 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 127 | 0.240 |
Why?
|
| Pain | 2 | 2020 | 41 | 0.240 |
Why?
|
| Sex Factors | 3 | 2021 | 227 | 0.240 |
Why?
|
| Logistic Models | 3 | 2020 | 254 | 0.230 |
Why?
|
| Counseling | 3 | 2020 | 143 | 0.230 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2014 | 472 | 0.230 |
Why?
|
| Comorbidity | 2 | 2019 | 188 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 244 | 0.220 |
Why?
|
| Immunity, Cellular | 2 | 2016 | 25 | 0.220 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 171 | 0.220 |
Why?
|
| Immunity, Humoral | 2 | 2023 | 42 | 0.220 |
Why?
|
| Proportional Hazards Models | 3 | 2014 | 163 | 0.220 |
Why?
|
| Thrombosis | 1 | 2024 | 47 | 0.220 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 112 | 0.210 |
Why?
|
| Risk Assessment | 4 | 2020 | 225 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2018 | 262 | 0.210 |
Why?
|
| Retrospective Studies | 6 | 2017 | 799 | 0.210 |
Why?
|
| Infant Nutritional Physiological Phenomena | 3 | 2014 | 17 | 0.200 |
Why?
|
| Stavudine | 2 | 2017 | 78 | 0.200 |
Why?
|
| Sexual Partners | 2 | 2015 | 215 | 0.190 |
Why?
|
| Health Personnel | 2 | 2024 | 231 | 0.190 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 2 | 2018 | 24 | 0.190 |
Why?
|
| Interleukin-2 | 2 | 2019 | 22 | 0.190 |
Why?
|
| Coinfection | 2 | 2015 | 276 | 0.180 |
Why?
|
| Canarypox virus | 1 | 2021 | 4 | 0.180 |
Why?
|
| Qualitative Research | 3 | 2018 | 321 | 0.180 |
Why?
|
| Neutropenia | 1 | 2021 | 9 | 0.180 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 8 | 0.180 |
Why?
|
| Cell Phone Use | 1 | 2021 | 6 | 0.180 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2009 | 195 | 0.180 |
Why?
|
| Work | 1 | 2020 | 9 | 0.180 |
Why?
|
| Treatment Failure | 1 | 2021 | 175 | 0.180 |
Why?
|
| RNA, Viral | 4 | 2011 | 303 | 0.180 |
Why?
|
| Chronic Pain | 1 | 2020 | 3 | 0.170 |
Why?
|
| Injections, Intramuscular | 2 | 2020 | 31 | 0.170 |
Why?
|
| Unemployment | 1 | 2020 | 10 | 0.170 |
Why?
|
| Financing, Government | 1 | 2020 | 11 | 0.170 |
Why?
|
| Gender-Based Violence | 1 | 2020 | 12 | 0.170 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 11 | 0.170 |
Why?
|
| Reminder Systems | 1 | 2020 | 8 | 0.170 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2020 | 10 | 0.170 |
Why?
|
| Time Factors | 3 | 2016 | 507 | 0.170 |
Why?
|
| Administration, Intravaginal | 1 | 2019 | 50 | 0.170 |
Why?
|
| CD40 Ligand | 1 | 2019 | 4 | 0.170 |
Why?
|
| Occupational Exposure | 1 | 2020 | 35 | 0.170 |
Why?
|
| Phagocytosis | 1 | 2019 | 15 | 0.170 |
Why?
|
| Thailand | 1 | 2019 | 26 | 0.170 |
Why?
|
| Cost of Illness | 2 | 2019 | 167 | 0.160 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 20 | 0.160 |
Why?
|
| Sex Distribution | 1 | 2019 | 89 | 0.160 |
Why?
|
| Age Distribution | 1 | 2019 | 107 | 0.160 |
Why?
|
| Survival Rate | 1 | 2019 | 96 | 0.160 |
Why?
|
| Antibody Formation | 1 | 2019 | 61 | 0.160 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 101 | 0.160 |
Why?
|
| Public Sector | 1 | 2020 | 82 | 0.160 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 65 | 0.160 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2019 | 36 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2019 | 49 | 0.160 |
Why?
|
| School Health Services | 2 | 2016 | 19 | 0.160 |
Why?
|
| Neutralization Tests | 1 | 2019 | 108 | 0.160 |
Why?
|
| Overweight | 1 | 2019 | 87 | 0.160 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 39 | 0.150 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2018 | 12 | 0.150 |
Why?
|
| Phylogeny | 2 | 2017 | 231 | 0.150 |
Why?
|
| Feasibility Studies | 2 | 2018 | 101 | 0.150 |
Why?
|
| Counselors | 1 | 2018 | 6 | 0.150 |
Why?
|
| Body Mass Index | 1 | 2019 | 321 | 0.150 |
Why?
|
| Primary Health Care | 2 | 2022 | 240 | 0.150 |
Why?
|
| Chemokines, CC | 2 | 2008 | 15 | 0.140 |
Why?
|
| Educational Status | 1 | 2017 | 68 | 0.140 |
Why?
|
| Viremia | 1 | 2017 | 66 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 239 | 0.140 |
Why?
|
| Developing Countries | 1 | 2020 | 400 | 0.140 |
Why?
|
| Immunoenzyme Techniques | 1 | 1997 | 21 | 0.140 |
Why?
|
| Dideoxynucleosides | 1 | 2017 | 29 | 0.140 |
Why?
|
| Medication Adherence | 1 | 2018 | 151 | 0.140 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 280 | 0.140 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2017 | 118 | 0.140 |
Why?
|
| Drug Utilization | 1 | 2017 | 10 | 0.140 |
Why?
|
| Crime Victims | 1 | 2017 | 5 | 0.140 |
Why?
|
| Bullying | 1 | 2017 | 9 | 0.140 |
Why?
|
| Rape | 1 | 2017 | 10 | 0.140 |
Why?
|
| Maternal Health Services | 2 | 2020 | 52 | 0.130 |
Why?
|
| Americas | 2 | 2021 | 10 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 106 | 0.130 |
Why?
|
| Chlamydia Infections | 1 | 2016 | 17 | 0.130 |
Why?
|
| Vaccinia | 1 | 2016 | 3 | 0.130 |
Why?
|
| Gonorrhea | 1 | 2016 | 20 | 0.130 |
Why?
|
| Perinatal Care | 2 | 2007 | 21 | 0.130 |
Why?
|
| Age Factors | 1 | 2017 | 370 | 0.130 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2016 | 2 | 0.130 |
Why?
|
| Obesity | 1 | 2019 | 367 | 0.130 |
Why?
|
| Diabetes, Gestational | 1 | 2017 | 38 | 0.130 |
Why?
|
| Genotype | 1 | 2017 | 442 | 0.130 |
Why?
|
| Haplotypes | 3 | 2014 | 125 | 0.130 |
Why?
|
| Immunoassay | 1 | 2015 | 28 | 0.120 |
Why?
|
| Immunization Programs | 1 | 2016 | 81 | 0.120 |
Why?
|
| Syphilis | 1 | 2015 | 14 | 0.120 |
Why?
|
| HLA-G Antigens | 1 | 2014 | 3 | 0.120 |
Why?
|
| Hypertension | 1 | 2019 | 419 | 0.120 |
Why?
|
| Genitalia | 1 | 2014 | 8 | 0.120 |
Why?
|
| Mucous Membrane | 1 | 2014 | 12 | 0.120 |
Why?
|
| Weaning | 1 | 2014 | 4 | 0.120 |
Why?
|
| Lost to Follow-Up | 1 | 2015 | 62 | 0.120 |
Why?
|
| Homosexuality | 1 | 2014 | 5 | 0.110 |
Why?
|
| Lamivudine | 2 | 2017 | 89 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 198 | 0.110 |
Why?
|
| Vaccines, Synthetic | 1 | 2014 | 12 | 0.110 |
Why?
|
| Heterosexuality | 1 | 2014 | 30 | 0.110 |
Why?
|
| Demography | 1 | 2014 | 105 | 0.110 |
Why?
|
| Interviews as Topic | 2 | 2018 | 203 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2014 | 179 | 0.110 |
Why?
|
| Specimen Handling | 1 | 2014 | 105 | 0.110 |
Why?
|
| Immune Tolerance | 1 | 2013 | 22 | 0.110 |
Why?
|
| Receptors, KIR | 1 | 2013 | 23 | 0.110 |
Why?
|
| Africa South of the Sahara | 2 | 2021 | 353 | 0.110 |
Why?
|
| INDEL Mutation | 2 | 2014 | 16 | 0.110 |
Why?
|
| Child | 6 | 2016 | 2242 | 0.110 |
Why?
|
| Floxacillin | 1 | 2013 | 6 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 13 | 0.100 |
Why?
|
| HIV Seropositivity | 2 | 2013 | 265 | 0.100 |
Why?
|
| Viral Proteins | 2 | 2010 | 30 | 0.100 |
Why?
|
| Zambia | 2 | 2023 | 115 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 39 | 0.100 |
Why?
|
| Hepatitis C | 1 | 2012 | 37 | 0.100 |
Why?
|
| Africa, Southern | 2 | 2010 | 91 | 0.100 |
Why?
|
| Prejudice | 1 | 2012 | 8 | 0.100 |
Why?
|
| Life Change Events | 1 | 2011 | 9 | 0.090 |
Why?
|
| Self Efficacy | 1 | 2011 | 11 | 0.090 |
Why?
|
| Chemokine CCL3 | 2 | 2008 | 23 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 253 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2010 | 48 | 0.090 |
Why?
|
| Hepatitis B | 1 | 2012 | 125 | 0.090 |
Why?
|
| Caribbean Region | 1 | 2010 | 11 | 0.090 |
Why?
|
| Australia | 1 | 2010 | 48 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 293 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2010 | 52 | 0.090 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2011 | 36 | 0.090 |
Why?
|
| Betacoronavirus | 2 | 2020 | 52 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2009 | 279 | 0.080 |
Why?
|
| Self Report | 2 | 2020 | 114 | 0.080 |
Why?
|
| Molecular Sequence Data | 4 | 2014 | 263 | 0.070 |
Why?
|
| Risk | 3 | 2013 | 87 | 0.070 |
Why?
|
| Gene Frequency | 3 | 2014 | 122 | 0.070 |
Why?
|
| Inpatients | 1 | 2007 | 30 | 0.070 |
Why?
|
| Palliative Care | 1 | 2007 | 52 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2007 | 7 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2007 | 56 | 0.070 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2007 | 6 | 0.070 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1986 | 1 | 0.070 |
Why?
|
| Equipment Contamination | 1 | 1986 | 5 | 0.070 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2007 | 40 | 0.070 |
Why?
|
| Infertility, Female | 1 | 2006 | 3 | 0.070 |
Why?
|
| Cytokines | 1 | 2007 | 107 | 0.070 |
Why?
|
| Epitopes | 1 | 2007 | 97 | 0.070 |
Why?
|
| Acidosis, Lactic | 1 | 2006 | 5 | 0.070 |
Why?
|
| Intraoperative Complications | 1 | 2006 | 8 | 0.070 |
Why?
|
| Didanosine | 1 | 2006 | 11 | 0.070 |
Why?
|
| Fatty Liver | 1 | 2006 | 8 | 0.070 |
Why?
|
| Cross Infection | 1 | 1986 | 52 | 0.070 |
Why?
|
| Base Sequence | 3 | 2014 | 149 | 0.060 |
Why?
|
| Health Resources | 1 | 2006 | 66 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2007 | 147 | 0.060 |
Why?
|
| Africa | 2 | 2017 | 376 | 0.060 |
Why?
|
| Bottle Feeding | 1 | 2005 | 4 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2006 | 55 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2005 | 149 | 0.060 |
Why?
|
| Biomarkers | 1 | 2006 | 327 | 0.060 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2004 | 7 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2004 | 8 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2004 | 10 | 0.060 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2004 | 12 | 0.060 |
Why?
|
| Gene Products, gag | 1 | 2004 | 11 | 0.060 |
Why?
|
| Adaptive Immunity | 1 | 2023 | 4 | 0.060 |
Why?
|
| Antibodies | 1 | 2023 | 25 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2017 | 1748 | 0.050 |
Why?
|
| Government Programs | 1 | 2023 | 30 | 0.050 |
Why?
|
| Systems Analysis | 1 | 2022 | 3 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 42 | 0.050 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2002 | 19 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2023 | 284 | 0.050 |
Why?
|
| Infant Mortality | 1 | 2002 | 97 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2021 | 13 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 89 | 0.050 |
Why?
|
| Europe | 1 | 2021 | 56 | 0.050 |
Why?
|
| Employment | 1 | 2021 | 27 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 16 | 0.040 |
Why?
|
| Injection Site Reaction | 1 | 2020 | 3 | 0.040 |
Why?
|
| Arthralgia | 1 | 2020 | 4 | 0.040 |
Why?
|
| Headache | 1 | 2020 | 7 | 0.040 |
Why?
|
| Child Health Services | 1 | 2020 | 35 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 31 | 0.040 |
Why?
|
| Text Messaging | 1 | 2020 | 25 | 0.040 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 1999 | 3 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 133 | 0.040 |
Why?
|
| Anxiety | 1 | 2020 | 40 | 0.040 |
Why?
|
| Taxes | 1 | 2020 | 73 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 111 | 0.040 |
Why?
|
| Food, Formulated | 1 | 1999 | 1 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 56 | 0.040 |
Why?
|
| Tuberculin Test | 1 | 1999 | 49 | 0.040 |
Why?
|
| Markov Chains | 1 | 1999 | 22 | 0.040 |
Why?
|
| Life Expectancy | 1 | 1999 | 31 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 124 | 0.040 |
Why?
|
| Coitus | 1 | 2018 | 15 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 34 | 0.040 |
Why?
|
| Data Collection | 1 | 2018 | 86 | 0.040 |
Why?
|
| Gene Dosage | 2 | 2008 | 23 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2017 | 42 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 25 | 0.040 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2017 | 3 | 0.030 |
Why?
|
| HIV Seronegativity | 2 | 2007 | 52 | 0.030 |
Why?
|
| Lopinavir | 1 | 2017 | 137 | 0.030 |
Why?
|
| Ritonavir | 1 | 2017 | 137 | 0.030 |
Why?
|
| United States | 1 | 2017 | 132 | 0.030 |
Why?
|
| Urine | 1 | 2016 | 6 | 0.030 |
Why?
|
| Chlamydia trachomatis | 1 | 2016 | 13 | 0.030 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2016 | 15 | 0.030 |
Why?
|
| Fetal Blood | 2 | 2006 | 27 | 0.030 |
Why?
|
| Sequence Alignment | 2 | 2008 | 59 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2016 | 80 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 89 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2016 | 34 | 0.030 |
Why?
|
| Tanzania | 1 | 2015 | 88 | 0.030 |
Why?
|
| Syphilis, Congenital | 1 | 2015 | 13 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 9 | 0.030 |
Why?
|
| Genome, Viral | 2 | 2007 | 64 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2014 | 40 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 385 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2013 | 5 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 2004 | 37 | 0.030 |
Why?
|
| Prognosis | 1 | 2014 | 199 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2004 | 139 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2014 | 480 | 0.030 |
Why?
|
| Alleles | 1 | 2013 | 143 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 127 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2012 | 64 | 0.030 |
Why?
|
| Rioprostil | 1 | 1991 | 1 | 0.020 |
Why?
|
| Esophagitis, Peptic | 1 | 1991 | 2 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 10 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 260 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 154 | 0.020 |
Why?
|
| Mutation | 1 | 2009 | 306 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 64 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 176 | 0.020 |
Why?
|
| Peptides | 1 | 2007 | 40 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2007 | 79 | 0.020 |
Why?
|
| Staphylococcus epidermidis | 1 | 1986 | 1 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 1986 | 3 | 0.020 |
Why?
|
| beta 2-Microglobulin | 1 | 2006 | 4 | 0.020 |
Why?
|
| Neopterin | 1 | 2006 | 4 | 0.020 |
Why?
|
| L-Selectin | 1 | 2006 | 7 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 14 | 0.020 |
Why?
|
| Mitogens | 1 | 2006 | 4 | 0.020 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2006 | 4 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2006 | 9 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 40 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2006 | 14 | 0.020 |
Why?
|
| Bacteria | 1 | 1986 | 47 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 54 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 60 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2006 | 26 | 0.020 |
Why?
|
| DNA | 1 | 2006 | 73 | 0.020 |
Why?
|
| Sepsis | 1 | 1986 | 102 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2004 | 6 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 22 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 2004 | 32 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2004 | 26 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 62 | 0.010 |
Why?
|
| Hospitalization | 1 | 2006 | 418 | 0.010 |
Why?
|
| Proviruses | 1 | 2003 | 6 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2003 | 16 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 27 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2003 | 16 | 0.010 |
Why?
|
| Binding Sites | 1 | 2003 | 43 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2003 | 27 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2003 | 165 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2003 | 175 | 0.010 |
Why?
|
| Aged | 1 | 2006 | 1740 | 0.010 |
Why?
|
| Patient Admission | 1 | 2000 | 11 | 0.010 |
Why?
|
| Skin Tests | 1 | 1999 | 14 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2000 | 76 | 0.010 |
Why?
|
| Cause of Death | 1 | 2000 | 221 | 0.010 |
Why?
|